| Type | Title | Date Released | |
|---|---|---|---|
6-K | Quantum BioPharma Files Supplement to Management Information Circular for Fractional Share Treatment and MVS Voting Power Threshold | ||
6-K | Quantum BioPharma Announces Court Consolidation of Lawsuit Against CIBC and RBC and Appointment of Lead Counsel | ||
6-K | Quantum BioPharma Signs Contract with Thermo Fisher Scientific’s Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis | ||
SCHEDULE 13G/A | AdvisorShares Trust (Filed by) | ||
6-K | Quantum BioPharma Licensee Unbuzzd Wellness Appoints Michael “Zappy” Zapolin as CEO and Prepares for Stock Exchange Listing | ||
6-K | Quantum BioPharma Announces Corporate Updates, Warrant Cancellation, Option Grant, and Closing of Fourth Debenture Tranche | ||
6-K | Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target | ||
6-K | Quantum BioPharma to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto | ||
6-K/A | Amendment incorporates Exhibit 99.1 into Registration Statement on Form F-3, with no other changes to the initial report. | ||
6-K/A | Amendment to Form 6-K incorporates Exhibit 99.1 into Registration Statement on Form F-3, with no other changes. | ||
6-K/A | Amendment to Form 6-K incorporates Exhibit 99.1 into Registration Statement on Form F-3, with no other changes. | ||
6-K | Quantum BioPharma Announces Voluntary Delisting from the Canadian Securities Exchange |
